Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Can It Field a Psoriasis Blockbuster?

Two other biologics mirroring this mechanism of action are in development across big pharma. Johnson & Johnson (NYSE:JNJ)’s CNTO 136 (sirukumab) for rheumatoid arthritis is in phase 3 trials that are expected to be completed in early 2016. Amgen, Inc. (NASDAQ:AMGN)’s AMG 139 for Crohn’s disease is in a phase 1 trial that will wrap up in September. The good news from a competition standpoint is that each drug is targeting a different immune disease. The distant bad news is that expanding indications for each drug could be met with muted enthusiasm given the established competition that may exist (should each gain approval).

Nonetheless, MK-3222 will be a first-in-class psoriasis option should it gain approval. It will be interesting to see how, if at all, the therapy improves upon Stelara by sparing interleukin 12. Several safety concerns have been specifically linked to agents that bind to the protein, according to Dr. Kim Papp of Probity Medical Research. Such therapies could potentially be a big step forward for patients and the industry.

The article Can Merck Field a Psoriasis Blockbuster? originally appeared on Fool.com and is written by Maxx Chatsko.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies.The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.